RMP114-mIgG1-D265A is a precision-engineered monoclonal antibody targeting murine PD-1, featuring a D265A mutation in the mIgG1 Fc region to enhance stability and minimize immunogenicity. This variant allows for specific PD-1 inhibition in preclinical models, minimizing off-target effects.
Designed for research, RMP114-mIgG1-D265A offers high specificity and purity, suitable for a variety of applications including in vitro and in vivo studies. It serves as a versatile tool for unraveling PD-1 signaling in murine models, supporting the development of novel immunotherapies.
In summary, RMP114-mIgG1-D265A provides researchers with a robust and low-immunogenicity alternative for studying PD-1 in immunology and oncology research.